RVX000222

apabetalone · Resverlogix Corp

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for RVX000222, covering 2014-04-02 to 2023-04-03. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease [Phase 2]